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SUMMARY
Ras activation is common to many human cancers and promotes cell proliferation and survival by initiating
multiple signaling cascades. Accordingly, Ras-transformed cells are generally considered too resourceful to
become addicted to a single effector. In contrast to this tenet, we now demonstrate an absolute, cell auton-
omous requirement for Raf-1 in the development and maintenance of Ras-induced skin epidermis tumors.
Mechanistically, Raf-1 functions as an endogenous inhibitor dimming the activity of the Rho-dependent
kinase Rok-a in the context of a Ras-induced Raf-1:Rok-a complex. Raf-1-induced Rok-a inhibition allows
the phosphorylation of STAT3 and Myc expression and promotes dedifferentiation in Ras-induced tumors.
These data link the Raf-1:Rok-a complex to STAT3/Myc activation and delineate a pathway crucial for cell
fate decision in Ras-induced tumorigenesis.INTRODUCTION
The epidermis shields the body from the potentially, or frankly,
harmful effects of the environment. Due to the wear and tear to
which it is subjected, the epidermis is in a constant state of
self-renewal. This process requires the proliferation of basal ker-
atinocytes, which, after detaching from the underlying basement
membrane of extracellular matrix, withdraw from the cell cycle
and differentiate while migrating toward the skin surface. The
disruption of the balance between keratinocyte proliferation
and their ability to differentiate and/or to undergo apoptosis
causes several pathological conditions, including tumorigenesis.
Squamous cell carcinoma (SCC), one of the most common
human skin cancers, results from such an imbalance between
proliferation, differentiation, and apoptosis (Ridky and Khavari,
2004). The pathways required to convert normal epidermis into
SCC are still incompletely defined, but there is strong evidence
indicating that activation of Ras signaling concomitant with inhi-
bition of NF-kB function is sufficient to transform normal human
epidermis into SCC (Green and Khavari, 2004).
Ras GTPases are activated by a variety of extracellular signals
and are mutated in 33% of human cancers. Activated Ras stim-ulates multiple effectors, including the Raf/MEK/ERK pathway,
the phosphoinositide-3 kinases (PI-3K)/Akt pathway, and the
guanine nucleotide exchange factors Ral-GDS and Tiam-1,
which lead to the activation of the small GTPases Ral and Rac,
respectively (Repasky et al., 2004). These different effectors of
Ras contribute to distinct aspects of transformation. While the
PI-3K pathway (Gupta et al., 2007; Sibilia et al., 2000) and
Ral-GDS (Gonzalez-Garcia et al., 2005) have been implicated in
cell survival, the ERK pathway has long been regarded as the
mitogenic branch of Ras signaling. Deregulation of this pathway
has been reported in more than 30% of common cancers. In the
specific case of SCC, themajority of spontaneous human tumors
display Ras and ERK activation in the absence of somatic Ras
mutations, suggesting that other factors, such as the overex-
pression of receptor tyrosine kinases, may activate the pathway
in tumors (Dajee et al., 2003).
Consistent with the mitogenic role attributed to the Ras/ERK
pathway, studies in mouse and human epidermal cells in vivo
have associated the activation of its components with increased
proliferation and decreased differentiation (Dajee et al., 2002;
Haase et al., 2001; Scholl et al., 2004; Tarutani et al., 2003),
although constitutive Ras/Raf activation can arrest growth andSIGNIFICANCE
Our data show that Ras-driven carcinogenesis requires the continuous presence of Raf-1 to restrain Rok-a activity and
prevent differentiation. Since Raf-1 is dispensable for epidermal homeostasis, this discovery paves the way for the design
ofmolecule-targeted therapies, whichmay include Raf-1 interference or allosteric inhibitors capable of disrupting the Raf-1:
Rok complex. The combination of chemotherapy and induction of tumor cell differentiation (differentiation therapy) has
revolutionized the treatment of leukemia. The complete differentiation induced by Raf-1 ablation in vivo provides proof of
principle that such differentiation therapy may be applied to solid tumors and raises hopes that a combination of Raf-1-tar-
geted and conventional therapiesmay be beneficial at least in the treatment of skin epidermis tumors containing active Ras.Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc. 149
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Ras Addicted to Raf-1Figure 1. Raf-1 Ablation in Keratinocytes
Prevents Chemically Induced Skin Carcino-
genesis
Eight- to twelve-week-old f/f, D/+ep and D/Dep
mice were subjected to chemical two-stage carci-
nogenesis with DMBA and TPA.
(A–D) D/Dep mice are completely resistant and
D/+ep mice are partially resistant to chemically-
induced skin carcinogenesis. (A) shows represen-
tative pictures of f/f, D/+ep and D/Dep animals. (B)
shows tumor incidence (C) shows the average
number of tumorspermouse. (D) shows tumor size.
(E) Lack ofmajor structural differences inD/+ep and
f/f tumor sections stained with hematoxylin and
eosin. The scale bar represents 100 mm.
(F) Mitotic index of f/f and D/+ep tumors. Prolifera-
tion was determined as the number of Ki67+ cells
permillimeter of basal membrane (BM). Threemilli-
meters of BM/mouse were analyzed. The plot
shows the results of the analysis of at least three
animals/genotype. Error bars indicate SD of the
mean. *p < 0.01 according to Student’s t test.induce features of terminal differentiation in cultured murine
keratinocytes (Lin and Lowe, 2001; Roper et al., 2001). Therefore,
the Raf/MEK/ERK arm of Ras signaling represents an attractive
target for the therapyof skincancer. Asacaveat to this statement,
human tumor cells harboring Rasmutations are quite resistant to
the inhibition of MEK (Solit et al., 2006), and while the Raf/MEK/
ERK pathway is important in tumor induction, other Ras effectors
may bemore relevant for themaintenance of established tumors,
at least in a xenograft model (Lim and Counter, 2005).
Rho familyGTPases have also been implicated in the control of
keratinocyte proliferation and differentiation, in the context of
both epidermal homeostasis and tumor development (Benitah
et al., 2005; Grossi et al., 2005; Lefort et al., 2007; Malliri et al.,
2002; Wu et al., 2006). Particularly, RhoA effectors have been re-
ported to both promote (McMullan et al., 2003) and antagonize
(Grossi et al., 2005;Lefort et al., 2007) keratinocytedifferentiation.
Well-characterized transgenic and chemical models of skin
carcinogenesis are available in which both the onset and
progression of tumors can be readily monitored. Recently, we
have generated a transgenic mouse model in which constitutive
activation of the endogenous Ras pathway is achieved by
the expression of a dominant active Son of Sevenless (SOS) in
the epidermis (K5-SOS-F transgenic mice; Sibilia et al., 2000).
In the presence of a functional EGFR, required to provide an
essential survival signal to tumor cells, K5-SOS-F mice develop
skin tumors that share featuresof humanSCC (Sibilia et al., 2000).
In the classical chemical carcinogenesis protocol, tumors are
initiated by the topical application of 7,12-dimethylbenz[a]
anthracene (DMBA), which causes a mutation in codon 61 of
the H-ras gene (Quintanilla et al., 1986), and promoted by the
repeated application of 12-O-tetradecanoylphorbol 13-acetate
(TPA). The development of these chemically induced tumors crit-
ically depends on inflammation (Mueller, 2006) and is reduced to
various degrees by the ablation of H-Ras (Ise et al., 2000), of the
Rac GEF Tiam-1 (Malliri et al., 2002), and of RalGDS (Gonzalez-
Garcia et al., 2005) in the whole animal. Whether the effects of150 Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc.Tiam1 or RalGDS ablation on carcinogenesis reflect the interrup-
tion of Ras signaling in the tumor target cell, or defects in acces-
sory cells (inflammatory cells and tumor-associated fibroblasts)
or a combination of both, remains to be conclusively established.
We have generated an epidermis-restricted Raf-1 knockout
(K5-Cre;c-raf-1flox/flox mice; hereafter referred to as D/Dep
[Ehrenreiter et al., 2005]), which enables us to investigate the
function of Raf-1 in keratinocytes during skin carcinogenesis.
D/Dep animals develop normally, except for a mild waved fur
phenotype that disappears after the first hair cycle and a signifi-
cant delay in repairing full-thickness wounds, which correlates
with amigratory defect of the keratinocytes. Themolecular basis
of this defect is the hyperactivity of the Rho effector Rok-a,
whose activation in wild-type cells is inhibited by Raf-1 in
a kinase-independent manner. In contrast, activation of ERK is
not affected by Raf-1 ablation (Ehrenreiter et al., 2005). Here,
we use the D/Dep animals as well as a mouse strain allowing
tamoxifen-inducible, epidermis-restricted Raf-1 ablation (Indra
et al., 1999) to investigate the role of Raf-1 in Ras-driven
epidermis carcinogenesis.
RESULTS
Raf-1 Ablation Prevents Ras-Dependent
Tumor Formation
Weassessed the role of Raf-1 in Ras-dependent tumor formation
by combining epidermis-restricted Raf-1 ablation (Dep, deleted in
epidermis [Ehrenreiter et al., 2005]) with the DMBA/TPA chemical
carcinogenesis protocol. In wild-type (f/f) mice, this protocol re-
sulted in the development of visible tumors within 6 weeks of
application of DMBA/TPA on dorsal skin, with a 50% penetrance
by week 13. In heterozygous (D/+ep) littermates tumor develop-
ment was severely retarded, starting at week 13 and reaching
an incidence of 50% by week 17 (Figure 1B). In addition, the
average number of tumors/mouse was significantly reduced in
the D/+ep group (two to three tumors/mouse compared with
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Ras Addicted to Raf-1five to six tumors/mouse in the wild-type cohort; Figures 1A and
1C). TheD/+ep tumors weremuch smaller than the f/f tumors and
most of them did not reach a volume of >5 mm3 at week 20
(Figures 1A and 1D). Tumor development was completely
blocked in homozygous D/Dep mice (Figures 1A and 1B). Histo-
logical examination at week 20 did not reveal any major differ-
ences in f/f and D/+ep tumors of similar size, all of which were
papillomas with a clear cut border, projecting above the
surrounding tissue (Figure 1E). The numbers of proliferating
Ki67+ cellswere slightly but significantly reduced inD/+ep tumors
(Figure 1F). Few apoptotic cells could be visualized by TUNEL
staining and their numbers were indistinguishable in f/f and
D/+ep tumors of the same size (see Figure S4A available online).
Thus, Raf-1 gene dosage is a critical determinant in DMBA-
induced tumor initiation, as shown by the reduced numbers
and delayed appearance of tumors in the heterozygotes, and
contributes to TPA-induced tumor promotion, as reflected by
the decreased proliferative index observed in D/+ep tumors.
Typically, DMBA induces tumor initiation by causing an acti-
vating mutation in codon 61 of the ras gene (Quintanilla et al.,
1986). Therefore, the data above strongly suggest a requirement
for Raf-1 in Ras-driven skin tumorigenesis. In the majority of
human SCCs, however, endogenous Ras signaling is activated
in the absence of such activating mutations (Dajee et al., 2003).
Tomimic this condition,weusedageneticmodel inwhichanacti-
vated form of theRas-GEFSOS is expressed under the control of
the K5 promoter in basal keratinocytes and in the outer root
sheath of the hair follicles, resulting in the synchronous formation
of fast-growing tumors, mostly papillomas (Sibilia et al., 2000).
These tumors grow predominantly on the tail, behind the ears,
and at sites subjected to scratching and biting. This distribution
has also been observed in transgenic animals expressing acti-
vated Ha-Ras from a keratin 10 (K10) promoter and suggests
that minor injuries promote tumor development (Bailleul et al.,
1990). In the 129 genetic background, 100% of f/f and D/+ep
mice developed visible tumors by the first and second month of
life, respectively (Figure 2A). As already noted for the chemical
carcinogenesis protocol, D/+ep tumors were much smaller than
those arising in f/f mice (Figure 2B). The D/Dep mice did not
develop any tumors until 6 months of age (Figure 2A); thereafter,
visible tumors started growing very slowly in 20% of the mice.
These tumorswere identified as escapers inwhich Raf-1 deletion
was incomplete and were not analyzed further (Figure S1).
We next analyzed small, medium, and large f/f and D/+ep
tumors (from 0.3–1.2 cm diameter). The gross histological
appearance of size-matched tumors was similar (Figure 2C);
however, the cells in the D/+ep lesions were smaller in size than
f/f tumor cells and showed a higher degree of compaction (Fig-
ure 2C). Loss of an orderly basal layer, keratin pearls, andclusters
or strands of K5+ tumor cells in the dermis, as well as microinva-
sions, were observed in the large f/f (Figures 2C, 2D, and 3D) and
occasionally in the D/+ep lesions (data not shown). D/+ep tumors
featured less BrdU+ proliferating cells, which were confined to
the basal layer (Figure 2E and data not shown). In addition,
whereas %25% of the cells in wild-type tumors expressed the
differentiation marker K10 (Grade 3–4 according to Broder’s
classification), D/+ep papillomas contained aroundR75% K10+
cells (Grade 1; Figure 2F). Conversely, the expression of integrin
b1, enriched in epidermal stem cells and correlated with the inhi-bition of keratinocyte differentiation (Levy et al., 2000), was
strongly increased in basal and suprabasal cells in f/f tumors,
but much less so in D/+ep papillomas (Figure 2G). K5-SOS-F;D/
Dep epidermis contained only sporadic integrin b1+ cells. An
increase in well-differentiated tumors could also be observed in
the DMBA/TPA model (5% of wild-type tumors were well
differentiated versus 36% D/+ep papillomas; Figure S2A). The
number of apoptotic cells was very low and indistinguishable in
f/f and D/+ep K5-SOS-F+ tumors (Figure S4B).
Raf-1 Is Necessary for the Maintenance
of K5-SOS-F-Induced Tumors
To determine whether Raf-1 was required for the maintenance
of the SOS-F-induced tumors, we used K5-SOS-F;K5-Cre-
ER(T);c-raf-1f/f mice, which express the Cre recombinase as
a fusion protein with the mutated ligand-binding domain of the
human estrogen receptor (ER). Binding to 4-hydroxy-tamoxifen
(TX), but not to estradiol, stimulates Cre activity (Indra et al.,
1999). To induce c-raf-1 ablation, we injected tumor-bearing
K5-SOS-F;K5-Cre-ER(T);c-raf-1f/f and their K5-SOS-F;c-raf-1f/f
littermates with TX (1 mg/day intraperitoneally, five consecutive
injections). At the time of injection (P26–P41), the diameter of
the lesions was between 0.5 and 0.75 cm. f/f tumors continued
to grow and doubled or even tripled their size within 2 weeks
from the last TX injection. In contrast, the lesions from condi-
tional knockout mice (D/DepTX) decreased in size and became
covered in white squames (Figures 3A and 3B), which eventually
disappeared (by week 7–8). Most lesions resolved completely
and never recurred throughout the life span of the animals. In
some cases, the bulk of the tumor was dramatically reduced,
but persisting small lesions became evident by week 6
(Figure S3A). The f/f allele was not completely converted to D/D
in these lesions, indicating that their persistence was due to
incomplete recombination (Figure S3B). Importantly, tumor
regression was not observed in mice harboring K5-SOS-F;K5-
Cre-ER(T) (B.M. Lichtenberger and M.S., unpublished data).
The regression of the D/DepTX tumors was accompanied by an
increase in cell compaction and tissue stratification (Figure 3D)
and by a striking decrease in the number of proliferating and in-
tegrin b1+ cells (Figures 3C and 3E), which became absolutely
restricted to the basal level (Figure 3E and data not shown).
Conversely, suprabasal K10 staining was restored to the
D/DepTX tumors (Figure 3F). The regressing tumors contained
hardly any apoptotic cells (Figure S4C). Together, the data indi-
cate that the regression of Raf-1 knockout tumors is due to
a massive increase in the terminal differentiation of the tumor
cells (Figure 3F), ultimately shed by the epidermis as squames,
which, in combination with the sharp decrease in cell prolifera-
tion (Figure 3C), results in net cell loss.
Raf-1 Ablation Promotes the Differentiation
of K5-SOS-F+ Keratinocytes In Vitro
The increased differentiation induced by the chronic or acute
ablation of Raf-1 in tumors could be a default program entered
by cells with a reduced proliferative ability; alternatively, an
intrinsic propensity of the cells to differentiate could bring about
the decrease in proliferation. To discriminate between these two
possibilities, we isolated primary keratinocytes from K5-SOS-F+
and K5-SOS-F mice to test their ability to proliferate andCancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc. 151
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Ras Addicted to Raf-1Figure 2. Raf-1 Ablation in Keratinocytes Prevents Tumor Formation and Tumor Progression in K5-SOS-F+ Mice
(A and B) Tumor incidence and load in K5-SOS-F;f/f, K5-SOS-F;D/+ep and K5-SOS-F;D/Dep animals.
(C and D) Histochemical and immunohistochemical analysis of size-matched f/f and D/+ep tumor sections stained with hematoxylin and eosin or with a K5 anti-
body for the basal layer visualization.
(E) Decreased mitotic index (BrdU+ cells/mm BM) in K5-SOS-F;D/+ep versus f/f tumors. The mitotic index of K5-SOS-F;D/Dep epidermis is indistinguishable from
that of f/f epidermis and is shown as a reference. The plot shows the results of the analysis of at least three animals/genotype.
(F and G) Increased differentiation in K5-SOS-F;D/+ep compared to K5-SOS-F;f/f tumors. Differentiation is shown as K10 positive layers (F). Undifferentiated
integrin b1+ cells in K5-SOS-F;D/+ep are reduced in number and confined to the basal layer compared to K5-SOS-F;f/f tumor sections (G). K5-SOS-F;D/Dep
epidermis is indistinguishable from that of f/f orD/D epidermis. Positive cells are stained in brown. The scale bar represents 100 mm. b, basal layer; sb, suprabasal
layer; mi, microinvasions; kp, keratin pearls. The dashed line indicates the border between epidermis and dermis. Error bars indicate SD of the mean. *p < 0.01
according to Student’s t test.differentiate in vitro. To avoidmeasuring a combination of effects
on proliferation, differentiation, and apoptosis, the impact of Raf-
1 ablation on the proliferative ability of keratinocytes in vitro was
determined by assessing the percentage of cells incorporating
BrdU. Only few K5-SOS-F+ keratinocytes, f/f or D/Dep of the
129/Sv background, proliferated in complete media (Figure 4A),
possibly because of oncogenic stress, which induces growth
arrest in premalignant cells (Collado et al., 2005). Raf-1 ablation
had no effect on the percentage of proliferating keratinocytes
cultured in complete media (Figure 4A), which was reduced by
chemical inhibition of the ERK but not of the Rok pathway
(Figure 4A). We next induced keratinocyte differentiation by
exposing cells of different genotypes to high concentrations of
CaCl2, a method widely used to recapitulate the biochemical
events accompanying the transition from the basal to the upper152 Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc.epidermal layers during differentiation in vivo. Differentiation was
measured as the number of involucrin+ cells developing in
the presence of 1.2 mM CaCl2 (Figures 4B and 4C). f/f and
D/Dep keratinocytes differentiated efficiently under these condi-
tions, whereas K5-SOS-F+;f/f keratinocytes failed to do so
(Figure 4C; Sibilia et al., 2000). In contrast, K5-SOS-F expression
did not prevent differentiation of Raf-1-deficient keratinocytes
(Figure 4C). Thus, Raf-1 ablation counteracts the K5-SOS-F-
mediated differentiation block in vivo and in vitro.
Raf-1 Is Required to Restrain Rok Signaling
in K5-SOS-F+ Cells and Epidermis
To gain insight into the mechanisms underlying the increased
differentiation of K5-SOS-F+;D/Dep cells, we monitored the acti-
vation of two signaling pathways connected to Ras/Raf and
Cancer Cell
Ras Addicted to Raf-1Figure 3. K5-SOS-F Tumors Are Addicted to
Raf-1
Tumor-bearing K5-SOS-F;D/DepTX mice and
K5-SOS-F;f/f were injected with tamoxifen for five
consecutive days and tumor regression was moni-
tored.
(A) Representative pictures of a K5-SOS-F;f/f and
K5-SOS-F;D/DepTX mouse after tamoxifen treat-
ment.Note the thick layerofsquamesonthesurface
of the regressing tumor. (X) Control mice had to be
culled because of the increasing tumor load.
(B) Quantification of tumor regression.
(C) Decreased cell proliferation (BrdU+ cells/mmof
BM) in K5-SOS-F;D/DepTX tumors 7 days after
tamoxifen injection. Error bars indicate SD of the
mean. *p < 0.01 according to Student’s t test.
(D–F) Sections of K5-SOS-F; f/f and of D/DepTX
tumors 7 days after tamoxifen injection. Note the
thick layer of squames in the regressing tumors.
(D) shows hematoxylin and eosin staining. Note
the increased cell and tissue compaction in
K5-SOS-F;D/DepTX tumors. (E) shows decreased
numbers of integrin b1+ cells, and (F) shows
increased differentiation (K10 expression) in
K5-SOS-F;D/DepTX tumors compared to
K5-SOS-F;f/f tumors. Positive cells are stained in
brown. The scale bar represents 100 mm.implicated in keratinocyte differentiation, namely ERK (Schmidt
et al., 2000; Wakamatsu et al., 2007) and Rok (McMullan et al.,
2003; Vaezi et al., 2002). Treatment of differentiating keratino-
cytes with chemical inhibitors of these pathways efficiently
blocked differentiation of cells of all four genotypes (Figure 4C).
Rok inhibition concomitantly increased proliferation in differenti-
ating cultures, whereas MEK/ERK inhibition completely abro-
gated it (Figure 4D). Both pathways were activated during differ-
entiation: ERK phosphorylation, however, increased only slightly
and was essentially indistinguishable in f/f and D/Dep cells
(Figure 4E, left panel). K5-SOS-F expression resulted in a strong
increase inERKphosphorylation thatwasnot affectedby the lack
of Raf-1 (Figure 4E, right panel). Activation of the Rok pathway
wasmeasured by the phosphorylation of the downstream targets
myosin light chain 2 (MLC2) and cofilin. MLC2 phosphorylation is
required for actin/myosin motor activation and enhances cell
contractility (Zhao andManser, 2005); cofilin is an actin-severing
protein whose phosphorylation, mediated by the Rok effector
LIMK, promotes actin polymerization. Cofilin phosphorylation
increases during the differentiation of cultured human keratino-
cytes and has been implicated in the compaction of the granular
layer of human epidermis in organotypic cultures (Honma et al.,
2006). Phosphorylation of MLC2 and (more slightly) of cofilin
increased during differentiation of wild-type and Raf-1-deficient
keratinocytes, in which it was already present before the induc-
tion of differentiation (Figure 4E, left panel).K5-SOS-F expression
suppressed phosphorylation, particularly of cofilin, but suppres-
sion was less severe in D/Dep keratinocytes (Figure 4E, right
panel). In addition, consistent with previous reports on the nega-
tive regulation of Rok by ERK (Mavria et al., 2006), the phosphor-
ylation of Rok downstream targets was increased by treating the
cells with a MEK/ERK inhibitor. In contrast, the Rok inhibitor
reduced the phosphorylation of MLC2 and cofilin without
affecting ERK phosphorylation (Figure 4E).Thus, the increased differentiation of Raf-1-deficient keratino-
cytes in vitro was paralleled by the activation of Rok downstream
targets, but not of the ERK pathway. To investigate whether this
was the case in vivo, we performed immunohistochemistry on
tumor sections from K5-SOS-F+ f/f, D/+ep or D/Dep mice. We
found that ERK activation was if anything increased in D/+ep
tumors and in the lesions regressing after Raf-1 ablation. In
both cases, phospho-ERK was localized mainly in the terminally
differentiating cells of the suprabasal layers, in contrast to the f/f
tumors in which phospho-ERK staining was observed in the
basal layer (Figures 5A and 5B). The pattern of ERK phosphory-
lation in K5-SOS-F;D/Dep epidermis was indistinguishable from
that of f/f orD/Dep epidermis not expressing theK5-SOS-F trans-
gene (Figure 5A).
In contrast to ERK, cofilin phosphorylation was clearly sup-
pressed in the f/f tumors compared to D/+ep tumors and to
K5-SOS-F;D/Dep epidermis (Figure 5C). A similar increase in
cofilin phosphorylation was noted in D/+ep tumors induced by
DMBA/TPA (Figure S2B). More importantly, cofilin phosphoryla-
tion was strongly induced in the regressing D/DepTX tumors,
concomitantly with the cell compaction and with the massive
differentiation caused by Raf-1 ablation (Figure 5D). These
results indicate that the expression of the K5-SOS-F transgene
restrains Rok signaling in keratinocytes in culture and in the
epidermis and that K5-SOS-F-mediated Rok inhibition is
disabled by chronic as well as acute Raf-1 ablation.
Raf-1 physically interacts with Rok-a (Ehrenreiter et al., 2005).
TomonitorwhetherK5-SOS-F increasedRaf-1:Rok-a interaction
in vivo, we prepared crude epidermal lysates and monitored
complex formation by assessing the presence of Raf-1 in endog-
enous Rok-a immunoprecipitates. The crude D/Dep lysates con-
tained a residual Raf-1 band (Figure 5E, left panel), which was
absent in pure keratinocyte cultures (Figure 4E) and therefore
results from contamination by other tissues, most likely dermisCancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc. 153
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Ras Addicted to Raf-1Figure 4. Raf-1 Ablation Enforces the Differentiation of K5-SOS-F+ Keratinocytes by a Mechanism Involving Rok Activation
(A) Proliferation of primary keratinocytes isolated from f/f, D/Dep, K5-SOS-F;f/f, and K5-SOS-F;D/Dep mice. Cells of all genotypes were cultured in complete
growth medium (c.g., continuously growing). Y-27632 (10 mM) or U0126 (10 mM) were added for inhibition of the Rok and the MEK/ERK pathway, respectively.
The percentage of proliferating cells was determined by BrdU incorporation.
(B–D) Raf-1 ablation promotes the differentiation of K5-SOS-F+ keratinocytes. The percentage of differentiating or proliferating keratinocytes was determined in
cultures exposed to 1.2 mM CaCl2 for the indicated time periods in the absence and presence of the inhibitors Y-27632 and U0126. Differentiating cells were
defined by the expression of involucrin+ (B and C; green; the scale bar represents 100 mm) and proliferating cells by BrdU+ incorporation (D). The plots in (A),
(C), and (D) show a quantification of the results obtained in three different experiments. Error bars indicate SD of the mean.
(E) Increased Rok pathway, but not ERK activation, inD/Dep keratinocytes. Immunoblot analysis of lysates prepared from keratinocytes differentiating in the pres-
ence or absence of the Rok or of theMEK/ERK inhibitor is shown. The figures on top of the pMLC2 and pCofilin panels represent a quantification of the intensity of
the bands, normalized to loading controls. The value corresponding to wild-type keratinocytes at time point 0 was arbitrarily defined as 1.and vessels. In K5-SOS-F+;f/f lysates, the Raf-1 band was
stronger and showed a slowermigration that has been correlated
with Raf-1 phosphorylation and activation (Figure 5E, left panel).
Since the K5-SOS-F+;f/f mice already bore tumors of different
sizes, the data indicate that Raf-1 increased in tumors, in line
with previous observations in human SCC (Riva et al., 1995;
Leicht et al., 2007), and that SOS-F expression drove Raf-1 hy-
perphosphorylation. A Raf-1:Rok-a complex was detectable
only in K5-SOS-F+;f/f lysates, and its amount was proportional
to Raf-1 expression and to the size of the tumor affecting the
epidermis (Figure 5E, right panel). Importantly, Rok-a kinase
activity was significantly higher in crude lysates of K5-SOS-
F+;D/Dep epidermis than in K5-SOS-F+;f/f lysates (Figure 5F).
Together, the data indicate that inhibition of Rok signaling by
Raf-1 is one of the strategies bywhich SOS and active Ras inhibit
keratinocyte differentiation.
Raf-1 Is Required for STAT3 Activation and Myc
Expression in K5-SOS-F Tumors
Besides its effects on the actin cytoskeleton, active (unphos-
phorylated) cofilin enhances the phosphorylation of the tran-
scription factor STAT3 and the expression of its target gene
c-myc in human psoriatic epidermis (Honma et al., 2006). This
mechanism had never been associated with tumorigenesis.154 Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc.Both STAT3 phosphorylation and Myc expression, however,
are increased in human SCC (Chen et al., 2008; Seethala et al.,
2008; Watt et al., 2008) and promote the development of
epidermal hyperplasia and/or malignant tumors in mice (Chan
et al., 2007, 2004; Sano et al., 1999; Watt et al., 2008). Therefore,
we next determined whether Raf-1 ablation had an impact on
STAT3 phosphorylation and Myc expression. pSTAT3+ and
Myc+ cells were present at very low levels in f/f and D/+ep
epidermis (data not shown) and in K5-SOS-F+;D/Dep epidermis,
in which they were essentially confined to the basal layer
(Figure 6). A substantial increase in pSTAT3+ and Myc+ cells
was detectable in the basal and suprabasal layers of K5-SOS-
F;f/f and D/+ep tumors, although the number of pSTAT3+ and
Myc+ cells remained significantly lower in the latter (Figure 6A).
More importantly, acute ablation of Raf-1 in established tumors
caused a dramatic decrease in both STAT3 phosphorylation
and Myc expression, and suprabasal staining was no longer
observed (Figure 6B).
Topical Application of a Rok Inhibitor Induces
Proliferation and Dedifferentiation
in K5-SOS-F;D/Dep Epidermis
The data above indicate that Raf-1 ablation limits cofilin activa-
tion, STAT3 phosphorylation, and Myc expression during
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Ras Addicted to Raf-1Figure 5. Chronic and Acute Raf-1 Ablation Induces the Phosphorylation of the Rok Downstream Target Cofilin in K5-SOS-F Tumors
(A and B) Raf-1 ablation does not affect ERK phosphorylation in K5-SOS-F tumors.
(C) Raf-1 ablation increases the phosphorylation (and inactivation) of cofilin in K5-SOS-F;D/+ep versus K5-SOS-F;f/f tumors. K5-SOS-F;D/Dep epidermis is indis-
tinguishable from that of f/f or D/Dep epidermis not expressing the K5-SOS-F transgene and is shown as a reference.
(D) Regressing K5-SOS-F;D/DepTX tumors contain high amounts of pCofilin+ cells (day 7 after tamoxifen treatment). ERK and cofilin phosphorylation were deter-
mined by immunohistochemistry of skin and tumor sections of the different genotypes as indicated. Positive cells are stained in brown. The scale bar represents
100 mm. The plots represent the results of the analysis of at least three animals/genotype, evaluatingR600 cells/mouse.
(E) Raf-1 interacts with Rok-a in K5-SOS-F+ epidermis. Rok-a was immunoprecipitated from crude epidermis lysates. The presence of Raf-1 and Rok-a was
detected by immunoblotting in whole-cell lysates (Input) and Rok-a immunoprecipitates (IP). In addition, SOS and SOS-F expression were determined in the
crude lysates. 14-3-3 is shown as a loading control. Note that in K5-SOS-F+ lysates Raf-1 is present as a doublet; the slower migrating form is associated
with phosphorylation and possibly activation. The Raf-1 band in the D/Dep lysates is probably due to contamination by other tissues (dermis or vessels). Arrow-
heads denote tumor-bearing mice. Tumor volume: 6, 98 mm3; 66, 236 mm3. Control tail volume: 78.5 mm3.
(F) Increased Rok-a activity in crude lysates of K-SOS-F;D/Dep epidermis. The kinase activity of Rok-a immunoprecipitates from 200 mg (left panel) or 400 mg of
crude epidermis lysates fromK-SOS-F+ f/f orD/Depmice was assessed using the long S6 peptide as a substrate. The amount of Rok-a in the immunoprecipitates
is shown below the graphs. Error bars indicate SD of the mean. *p < 0.01 according to Student’s t test.Ras-induced tumor development. This is probably due to Rok-
a hyperactivation. To determine whether Rok-a hyperactivation
limits activation of the cofilin/STAT3/Myc pathway and tumor
development in vivo, we applied the Rok inhibitor Y-27632 on
the right ear of K5-SOS-F;D/+ep or K5-SOS-F;D/Dep mice. The
left ear was treated with DMSO as a vehicle and as skin perme-
ation enhancer. We chose the ears for this treatment because
the epidermis is thinner than that of other body sites (Porter
et al., 1998). A thinner epidermis increases the chances of the
inhibitor to reach the basal layer and therefore the target cells.DMSO itself caused skin irritation and some proliferation (3- to
4-fold increase) of the epidermis, as previously described
(Lashmar et al., 1989). Y-27632, however, induced a significant
increase in the proliferation of K5-SOS-F;D/+ep and K5-SOS-
F;D/Dep epidermis (Figure 7A), measured both as epidermal
thickness and as a percentage of BrdU+ cells. Conversely, differ-
entiation, defined by the percentage of K10+ epidermal layers,
was strongly reduced (Figure 7B). The inhibitor also caused
a reduction in the percentage of pCofilin+ cells as well as a
decrease in the intensity of pCofilin staining. The latter aspectCancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc. 155
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(Figure 7C), which therefore understates the contribution of Rok
to cofilin phosphorylation in vivo. Both STAT3 phosphorylation
and Myc expression were strongly increased in the inhibitor-
treated epidermis (Figures 7D and 7E), indicating that the cofi-
lin/STAT3/Myc pathway is inhibited by Rok during the dediffer-
entiation of the keratinocytes required for tumor development.
The D/Dep animals were more resistant to the Rok inhibitor
than the D/+ep mice and had to be treated for a longer time
period (6 weeks instead of 2) to achieve similar results. This is
consistent with the idea that in D/+ep epidermis the residual inhi-
bition of Rok by Raf-1 synergizes with Y-27632 to allow dediffer-
entiation/proliferation, whereas the complete absence of Raf-1
in the D/Dep epidermis renders it less permissive to the action
of the inhibitor.
Figure 6. Chronic and Acute Raf-1 Ablation
Decreases the Phosphorylation of STAT3
and the Expression of Myc in K5-SOS-F
Tumors
(A) Raf-1 ablation decreases the phosphorylation
of STAT3 (upper panel) and the expression of the
STAT3 target Myc (lower panel) in K5-SOS-F;D/
+ep versus K5-SOS-F;f/f tumors. K5-SOS-F;D/
Dep epidermis is indistinguishable from epidermis
not expressing the K5-SOS-F transgene. The
scale bar represents 100 mm.
(B) STAT3 phosphorylation (upper panel) and Myc
expression (lower panel) are dramatically reduced
in regressing K5-SOS-F;D/DepTX tumors (day 7
after tamoxifen treatment). STAT3 phosphoryla-
tion and Myc expression were determined by
immunohistochemistry of skin and tumor sections
of the different genotypes as indicated. Positive
cells are stained in brown. The scale bar repre-
sents 100 mm. The plots represent the results of
the analysis of at least three animals/genotype,
evaluating R600 cells/mouse. Error bars indicate
SD of the mean. *p < 0.01 according to Student’s
t tests.
Together, the data link Raf-1 ablation
with the activation of Rok, the inhibition
of the cofilin/STAT3/Myc pathway, and
the increased differentiation of Ras-
induced tumors in vivo (Figure 7F).
DISCUSSION
The data above prove that in the mouse
Raf-1 is required for the establishment
and maintenance of skin tumors driven
by the activation of Ras, achieved either
by somatic mutation (DMBA/TPA model)
or, more similar to the situation in human
SCC, by the constitutive activation of the
endogenous Ras pathway. Raf-1 ablation
completely precludes tumor formation in
both models and Raf-1 heterozygosity
reduces it. More importantly, Raf-1 abla-
tion causes the complete regression of
established tumors. In contrast to the results obtained by inter-
fering with other Ras effectors (Gonzalez-Garcia et al., 2005;
Gupta et al., 2007; Malliri et al., 2002), the requirement for
Raf-1 in Ras-driven carcinogenesis is absolute and it extends
to tumor maintenance.
Raf-1 is also the first Ras effector for which a cell-autonomous
requirement has been clearly demonstrated by the concomitant
activation of Ras and ablation of Raf-1 in the same cell, the K5+
keratinocyte, in the context of an otherwise intact host. This does
not, per se, rule out the possibility that a defective interaction of
the Raf-1-deficient tumor cells with the stromamay contribute to
the block of tumor development and maintenance, as we have
recently described for B-Raf-deficient insulinomas (Sobczak
et al., 2008). Such defects, however, could not explain the lack
of primary tumor development observed in the D/Dep epidermis156 Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc.
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established tumors. This accelerated differentiation can also
be observed in cultured Raf-1-deficient keratinocytes, confirm-
ing the cell-autonomous nature of the defect (Figure 4).
In contrast to other Ras downstream targets such as RalGDS
or PI-3K, whose main role is to support cell survival (Gonzalez-
Garcia et al., 2005; Gupta et al., 2007), Raf-1 promotes tumor
development by blocking differentiation. Surprisingly, this block
in differentiation does not correlate with changes in the best-
studied Raf downstream pathway MEK/ERK, whose activation
was unchanged in D/Dep epidermis and cultured keratinocytes.
Instead, the Raf-1-dependent, SOS-F-induced differentiation
block correlates with the reduced activation of Rok downstream
targets, both in vivo in tumors and in keratinocytes differentiating
in culture (Figures 4–6). In vivo treatment with a chemical Rok
inhibitor induced dedifferentiation and increased proliferation in
K5-SOS-F;D/Dep epidermis (Figure 7), establishing a causal rela-
tionship between Rok inhibition by Raf-1 and the SOS-F-
induced differentiation block. Rok inhibition reduced cofilin
phosphorylation and increased STAT3 phosphorylation and
Myc expression. Activation of the cofilin/STAT3/Myc pathway
had been previously reported in hyperproliferating psoriatic
epidermis, in which it blocks cell compaction (Honma et al.,
2006), but it had never been implicated in tumorigenesis. Our
data show that activation of this pathway correlates with a block
in keratinocyte differentiation and increased proliferation in Ras-
induced tumors in vivo, but we do not interpret them tomean that
the inhibition of the cofilin/STAT3/Myc pathway is the only rele-
vant event downstream of Rok in epidermal carcinogenesis;
other targets of Rok not tested here, like the transcription factor
NF-kB,may be equally relevant in this context (Dajee et al., 2003;
van Hogerlinden et al., 1999).
Together, the data support the hypothesis that Raf-1 is de-
ployed by activated Ras to counteract the activity of Rok by
direct binding as previously reported (Ehrenreiter et al., 2005).
Consistent with this theory, the interaction between Raf-1 and
Rok-a was increased, and Rok-a activity decreased, in the
K5-SOS-F+ epidermis. Thus, one of the crucial functions of
activated Ras in tumorigenesis is to prevent keratinocyte differ-
entiation by restraining Rok activity, and Raf-1 is essential in this
process (Figure 7F).
A role of Rok in cell differentiation and in the determination of
cell fate has been recently emerging in other systems. Rok
inhibition promotes the survival of human dissociated stem
cells (Watanabe et al., 2007), perturbs epidermal stratification
(Vaezi et al., 2002), and counteracts keratinocyte differentiation
(Figures 4B and 7B; Honma et al., 2006; McMullan et al.,
2003), whereas active Rok-a promotes it (McMullan et al., 2003).
These observations are in line with a negative effect of Rok
activation on tumorigenesis. In contrast, Rok is often upregu-
lated in tumors (Sahai, 2005) and its activation can promote
proliferation, invasion, and angiogenesis in xenograft models
using human tumor cells (Croft et al., 2004; Itoh et al., 1999; Le-
fort et al., 2007). It is possible that the role of Rok in tumorigen-
esis is highly context dependent and that Rok activation may
promote tumorigenesis when combined with mutations other
than Ras activation. Alternatively, oncogenes are known to
induce opposing signals, such as mitogenic and antiproliferative
stress responses, the best known of which is senescence.Indeed, some of the genes synergistically upregulated by the
combination of mutant p53 and Ras proteins in tumor cell lines
have recently been proven antitumorigenic (McMurray et al.,
2008). It is conceivable that the Rok overexpression observed
in tumors may have originally been part of such an antiprolifera-
tive program. Be that as it may, the fact that Rok inhibition allows
dedifferentiation and proliferation of SOS-F+ epidermis, even in
the absence of Raf-1, sounds a note of caution for the use of Rok
inhibitors in the treatment of tumors, particularly of those relying
on Ras activation.
Ras-driven skin tumors are addicted to Raf-1 in its role of
endogenous Rok inhibitor, whereas Raf-1 signaling is not essen-
tial for epidermal development and homeostasis (Ehrenreiter
et al., 2005). This discovery paves the way for the design of
molecule-targeted therapies, which may include Raf-1 interfer-
ence or allosteric inhibitors capable of disrupting the Raf-1:Rok
complex. The treatment of cancer by inducing tumor cell differ-
entiation in combination with chemotherapy has revolutionized
the treatment of leukemia (Wang and Chen, 2008), but solid
tumors have so far proven resistant. The complete differentiation
induced by Raf-1 ablation in vivo raises hopes that combinations
of Raf-1-targeted and conventional therapies may be successful
at least in the treatment of Ras-driven skin epidermis tumors.
EXPERIMENTAL PROCEDURES
Mouse Strains, Genotyping, and Tumor Models
c-raf-1 D/Dep or D/+ep, K5-SOS-F, and K5-Cre-er(T) mice and the respective
genotyping have been described (Ehrenreiter et al., 2005; Indra et al., 1999;
Sibilia et al., 2000). All strains were maintained on a 129Sv background. For
chemical two-stage carcinogenesis, mice were shaved 3 days before initiation
with DMBA (25 mg/200ml acetone; Sigma) applied to the dorsal skin. Beginning
3 days later, TPA (6 mg/100ml acetone; Sigma) was applied twice per week for
20 weeks. Control mice were treated with acetone (Hsieh et al., 2006). Onset,
number, and size of tumors were monitored at least twice a week. Tumors
developing in D/Dep mice or relapsing after TX treatment were genotyped
isolating the DNA from paraffin section and extending the c-raf-1 PCR protocol
by ten additional cycles to increase amplification. All animal experiments were
performed in accordance with a protocol authorized by the AustrianMinistry of
Science and Communications, following the approval by the national Ethical
Committee for Animal Experimentation.
Histological Analysis
Hematoxylin/eosin staining and immunohistochemistry were performed on
3-mm-thick sections of 4% paraformaldehyde-fixed and paraffin-embedded
tissues. Tail sections were decalcified by incubation of trimmed paraffin blocks
for 10–15 min on paper towels soaked in 1 N HCl. Staining with the following
antibodies was performed: a-BrdU (1:100; Zymed); a-c-myc (1:250; Milipore);
a-E-cadherin (1:150; Santa Cruz); a-integrin b1 (1:50; BD Biosciences); a-K10
(1:500; BabCo); a-Ki67 (1:1000; Novocastra); a-pCofilin (Ser3, 1:50; Santa
Cruz); a-pERK (Thr202/Tyr204, 1:50; Cell Signaling); and a-pSTAT3 (Tyr705,
1:100; Cell Signaling). For detection, we used the DAKO EnVision peroxidase
system, followed by incubation with 0.01% diaminobenzidine (Sigma), in
conjunction with avidin-biotinylated enzyme complex (Vector Laboratories)
for biotinylated antibodies. Sections were counterstained with hematoxylin.
BrdU incorporation was determined in mice injected with BrdU (12.5 mg/g
body weight) 1 hr prior to tissue isolation.
Keratinocyte Isolation and Culture
Primary mouse keratinocytes were isolated from 18- to 21-day-old mice as
previously described (Sibilia et al., 2000), plated at a density of 6 3 106
cells/100 mm plate, and cultured in MEM (Sigma) containing 1 mg/ml insulin
(Sigma), 5 ng/ml EGF (Roche), 5mg/ml transferrin (Sigma), 10 mMphosphoetha-
nolamine (Sigma), 10 mM ethanolamine (Sigma), 0.36 mg/ml hydrocortisoneCancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc. 157
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Ras Addicted to Raf-1Figure 7. A Rok Inhibitor Induces Proliferation, Dedifferentiation, and Activation of the Cofilin/STAT3/Myc Pathway in the Epidermis of
K5-SOS-F;D/+ep and K5-SOS-F;D/Dep Mice
Mice were treated with DMSO as a vehicle (left ear) or with Y-27632 (40 mM in DMSO; right ear) twice a day for 2 (K5-SOS-F;D/+ep) or 6 weeks (K5-SOS-F;D/Dep).
(A) Y-27632 causes proliferation of K5-SOS-F;D/+ep and K5-SOS-F;D/Dep epidermis. Proliferation was assessed both by counting the numbers of BrdU+ cells
and by measuring epidermal thickness.
(B) Y-27632 causes dedifferentiation of K5-SOS-F;D/+ep and K5-SOS-F;D/Dep epidermis. Differentiation was assessed as the number of K10+ epidermal layers.
In (A) and (B), proliferation and differentiation are expressed as a percentage of DMSO controls.158 Cancer Cell 16, 149–160, August 4, 2009 ª2009 Elsevier Inc.
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Ras Addicted to Raf-1(Calbiochem), glutamine (Glutamax-I; Invitrogen), Pen/Strep (Invitrogen), and
6% chelated FCS (Chelex 100 Resin; Bio-Rad). The culture medium was
exchanged every second day. For inducing differentiation, cells were trans-
ferred into starvationmedium (containing only 2%chelated FCS and no growth
factors) and treated with 1.2 mM CaCl2 for different time periods. The Rok-
a inhibitor Y-27632 (Calbiochem) and the MEK inhibitor U0126 (Cell Signaling)
were added to the medium at a final concentration of 10 mM.
For the analysis of differentiation, cells were fixed in 4% PFA, permeabilized
(0.2% Triton X-100), and blocked with 1% BSA before incubation with primary
antibodies (a-Involucrin, 1:500; BabCo) followed by detection with the
secondary FITC antibody (a-rabbit alexa 448 nm, 1:1500; Molecular Probes)
and mounted with ProLong Antifade (Promega). Microscopical analysis was
performed with an Axiovert 200 (Carl Zeiss MicroImaging, Inc.) equipped
with an AxioCam. Images were acquired with the AxioVision Software (Carl
Zeiss MicroImaging, Inc.) Proliferation was assessed by the In Situ Cell Prolif-
eration Kit FLUOS (Roche) according to the manufacturer’s recommendation.
Cells were examined by light microscopy (Zeiss AxioVision; Carl Zeiss
MicroImaging, Inc.), and the number of BrdU+ cells was quantified with the
AutoMeasure software (Carl Zeiss MicroImaging, Inc.).
Rok-a Immunoprecipitation and Immunoprecipitation Kinase
Assays
Crude epidermis lysates were prepared from the tail of 17-day-old mice. In
brief, the skin was digested with trypsin to separate the epidermis from the
dermis. The epidermis was placed in lysis buffer (200 mM Tris-HCl [pH 7.4],
2 mMEDTA, and 1% Triton X-100, supplemented with protease and phospha-
tase inhibitors) and homogenized with the PreCellys24 homogenizer (PeqLab).
Rok-a immunoprecipitateswere prepared from1200 mgof proteinwith aRok-a
antibody (Upstate) and analyzed by immunoblotting or assayed for Rok-a
kinase activity with the long S6 kinase (Upstate) as a substrate according to
the manufacturer’s instructions. The Rho kinase inhibitor Y-27632 (20 mMfinal)
was used for assessment of Rok-a-specific kinase activity.
Immunoblotting
Membranes were probed with a-Cofilin (Abcam); a-panERK, a-Raf-1, a-Rok-a
(Transduction Labs); a-panRasV12 (Calbiochem); a-pCofilin, a-pMLC2
(Santa Cruz); a-pERK (Cell Signaling); and a-SOS (BDBiosciences). After incu-
bation with the appropriate secondary antibody, the antigens were visualized
by ECL (Pierce).
Statistical Analysis
All values are expressed as mean (±SD) of at least three independent experi-
ments. p values were calculated with the two-tailed Student’s t test. A p value
% 0.05 is considered statistically significant.
SUPPLEMENTAL DATA
Supplemental Data contain four figures and can be foundwith this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00183-4.
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